Your patients should pay no more than $40*

Avadel is committed to helping patients access NOCTIVA™ (desmopressin acetate) Nasal Spray, regardless of their insurance coverage.

TO ENSURE YOUR PATIENT CAN GET NOCTIVA, FOLLOW THESE INSTRUCTIONS:
IF YOUR PATIENT HAS
commercial insurance

Send prescription to the patient’s preferred retail pharmacy.

Make sure every patient leaves your office with a NOCTIVA co-pay card.

Tell your patients to present the co-pay card to their pharmacist to save, even if their insurance doesn’t cover NOCTIVA.

Co-pay cards
There are multiple ways for your patients to get a co-pay card.

Download the card and print it out for your patients.

Get Co-pay Card

Get cards delivered to your office by contacting us.

Send a Request

Have your patient download one at www.NOCTIVA.com, or text “NOCTIVA” to 46822 to receive it on their phone.

IF YOUR PATIENT HAS
Medicare Part D coverage

The NOCTIVA Care+ Program was designed to help Medicare, underinsured, and uninsured patients access NOCTIVA at an affordable price.

Send the prescription to Eagle Pharmacy via eRX, or FAX a completed NOCTIVA enrollment form.

FAX a completed Medicare Tier Exception form and any supporting clinical evidence regarding your patient’s diagnosis to Eagle Pharmacy.

EAGLE PHARMACY
350 Eagles Landing Dr
Lakeland, FL 33810

NPI: 1487905840
NCPDP: 5711975
Fax: 866-848-8927
Tel: 855-250-2484

IMPORTANT
  • DO NOT send Medicare Part D prescriptions to the patient’s local retail pharmacy
  • If you have questions about a patient’s prescription, call Eagle Pharmacy directly
  • Your patients should expect a call from “Eagle Pharmacy”
  • Eagle Pharmacy will complete a benefit investigation to determine your patient’s insurance coverage for NOCTIVA
  • If their co-pay is affordable, the prescription will be sent to their local pharmacy to fill
  • If the patient’s insurance does not cover NOCTIVA, or the co-pay isn’t affordable, the patient will be enrolled in our unique cash-pay program. They will pay for NOCTIVA with their credit card over the phone, and NOCTIVA will be delivered directly to their home each month

Terms and conditions may apply. Avadel reserves the right to amend or cancel these programs, including the maximum co-pay amount of $40, at any time without notice. Patients with federally funded insurance coverage such as Medicare, Medicaid, and TRICARE may have co-payment amounts >$40 if the patient chooses to use these benefits in order to fill the prescription at their in-network retail or mail-order pharmacy. The $40 cash-pay program is only available through Eagle Pharmacy and does not utilize the patient’s insurance benefits.

Take action

Many of your patients could be waking up tonight because of nocturia due to nocturnal polyuria. With NOCTIVA, you could reduce its impact.1

Take action

Many of your patients could be waking up tonight because of nocturia due to nocturnal polyuria. With NOCTIVA, you could reduce its impact.1

Next up

Find resources for your office and patients.

Resources
REFERENCE

1. NOCTIVA [package insert]. Chesterfield, MO: Avadel Specialty Pharmaceuticals, LLC; 2017.

Order Samples
INDICATION AND IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

WARNING: HYPONATREMIA

See full prescribing information for complete boxed warning.

  • NOCTIVA can cause hyponatremia, which may be life-threatening if severe.
  • NOCTIVA is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids.
  • Ensure serum sodium is normal before starting or resuming NOCTIVA. Measure serum sodium within seven days and approximately one month after initiating therapy or increasing the dose, and periodically during treatment. More frequently monitor serum sodium in patients 65 years of age and older and in patients at increased risk of hyponatremia.
  • If hyponatremia occurs, NOCTIVA may need to be temporarily or permanently discontinued.
Indications and usage

NOCTIVA is a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void.

Limitation of Use: Not studied in patients younger than 50 years of age.

Contraindications
  • Hyponatremia or a history of hyponatremia
  • Polydipsia
  • Primary nocturnal enuresis
  • Concomitant use with loop diuretics or systemic or inhaled glucocorticoids
  • Estimated glomerular filtration rate below 50 mL/min/1.73 m2
  • Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
  • During illnesses that can cause fluid or electrolyte imbalance
  • New York Heart Association (NYHA) Class II-IV congestive heart failure
  • Uncontrolled hypertension
Warnings and Precautions
  • Fluid retention: Not recommended in patients at risk of increased intracranial pressure or history of urinary retention. Monitor volume status in patients with NYHA Class I congestive heart failure.
  • Nasal conditions: Discontinue in patients with concurrent nasal conditions that may increase absorption, until resolved.
Adverse Reactions

Common adverse reactions in clinical trials (incidence >2%) included nasal discomfort, nasopharyngitis, nasal congestion, sneezing, hypertension / blood pressure increased, back pain, epistaxis, bronchitis and dizziness.

Drug Interactions

Monitor serum sodium more frequently when NOCTIVA is concomitantly used with drugs that may cause water retention and increase the risk for hyponatremia (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, nonsteroidal anti-inflammatories, lamotrigine and carbamazepine).

Use in Specific Populations
  • Pregnancy: Use of NOCTIVA is not recommended.
  • Pediatric: Do not use NOCTIVA for primary nocturnal enuresis in children.

To report SUSPECTED ADVERSE REACTIONS, contact Avadel at 1-877-638-4579 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATION AND IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

WARNING: HYPONATREMIA

See full prescribing information for complete boxed warning.

  • NOCTIVA can cause hyponatremia, which may be life-threatening if severe.
  • NOCTIVA is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids.
  • Ensure serum sodium is normal before starting or resuming NOCTIVA. Measure serum sodium within seven days and approximately one month after initiating therapy or increasing the dose, and periodically during treatment. More frequently monitor serum sodium in patients 65 years of age and older and in patients at increased risk of hyponatremia.
  • If hyponatremia occurs, NOCTIVA may need to be temporarily or permanently discontinued.
Indications and usage

NOCTIVA is a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void.

Limitation of Use: Not studied in patients younger than 50 years of age.

Contraindications
  • Hyponatremia or a history of hyponatremia
  • Polydipsia
  • Primary nocturnal enuresis
  • Concomitant use with loop diuretics or systemic or inhaled glucocorticoids
  • Estimated glomerular filtration rate below 50 mL/min/1.73 m2
  • Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
  • During illnesses that can cause fluid or electrolyte imbalance
  • New York Heart Association (NYHA) Class II-IV congestive heart failure
  • Uncontrolled hypertension
Warnings and Precautions
  • Fluid retention: Not recommended in patients at risk of increased intracranial pressure or history of urinary retention. Monitor volume status in patients with NYHA Class I congestive heart failure.
  • Nasal conditions: Discontinue in patients with concurrent nasal conditions that may increase absorption, until resolved.
Adverse Reactions

Common adverse reactions in clinical trials (incidence >2%) included nasal discomfort, nasopharyngitis, nasal congestion, sneezing, hypertension / blood pressure increased, back pain, epistaxis, bronchitis and dizziness.

Drug Interactions

Monitor serum sodium more frequently when NOCTIVA is concomitantly used with drugs that may cause water retention and increase the risk for hyponatremia (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, nonsteroidal anti-inflammatories, lamotrigine and carbamazepine).

Use in Specific Populations
  • Pregnancy: Use of NOCTIVA is not recommended.
  • Pediatric: Do not use NOCTIVA for primary nocturnal enuresis in children.

To report SUSPECTED ADVERSE REACTIONS, contact Avadel at 1-877-638-4579 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.